Marina Biotech, Inc. (OTCMKTS:MRNA) Files An 8-K Other Events

Item 8.01 Other Events.

On March 4 and March 5, 2017, Dr. Vuong Trieu, the Chairman of
the Board of Directors of Marina Biotech, Inc., presented a
poster on the clinical development of Celecoxib-Lisinopril FDC
(IT-102) and Celecoxib-Olmesartan FDC (IT-103) against combined
arthritis / hypertension at the 7^th International
Conference on Fixed Combination in the Treatment of Hypertension,
Dyslipidemia and Diabetes Mellitus in Cannes, France. A copy of
the presentation is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

About Marina Biotech, Inc. (OTCMKTS:MRNA)

Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).

Marina Biotech, Inc. (OTCMKTS:MRNA) Recent Trading Information

Marina Biotech, Inc. (OTCMKTS:MRNA) closed its last trading session 00.000 at 0.260 with 151,711 shares trading hands.